These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35968582)

  • 1. Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative.
    Ballinger TJ; Djuric Z; Sardesai S; Hovey KM; Andrews CA; Brasky TM; Zhang JT; Rohan TE; Saquib N; Shadyab AH; Simon M; Wactawski-Wende J; Wallace R; Kato I
    Nutr Cancer; 2023; 75(1):265-275. PubMed ID: 35968582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histamine H
    Larson SR; Vasbinder AL; Reding KW; Leary PJ; Branch KR; Shadyab AH; Johnson KC; Haring B; Wallace R; Manson JE; Anderson G; Cheng RK
    J Am Heart Assoc; 2022 Mar; 11(5):e024270. PubMed ID: 35191329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of proton pump inhibitors versus histamine-2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers.
    Fan HP; Zhou Y; Chen ML; Qiu KH; Feng X; Zhou C; Zhu ML; Huang RZ; Hu TY
    Pharmacotherapy; 2024 Jul; 44(7):539-548. PubMed ID: 38899757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.
    Babic A; Zhang X; Morales-Oyarvide V; Yuan C; Khalaf N; Khalili H; Lochhead P; Chan AT; Ogino S; Wolpin BM; Wu K; Fuchs CS; Giovannucci EL; Stampfer MJ; Ng K
    Br J Cancer; 2020 Sep; 123(5):844-851. PubMed ID: 32541871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
    Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study.
    Chen LY; Lin HJ; Wu WT; Chen YC; Chen CL; Kao J; You SL; Chou YC; Sun CA
    Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33182362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
    Ngwenya S; Simin J; Brusselaers N
    Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study.
    Zeng R; Ma Y; Zhang L; Luo D; Jiang R; Wu H; Zhuo Z; Yang Q; Li J; Leung FW; Duan C; Sha W; Chen H
    Elife; 2024 Jul; 13():. PubMed ID: 39012339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton Pump Inhibitor Use, H
    Paik JM; Rosen HN; Gordon CM; Curhan GC
    Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
    Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
    Aliment Pharmacol Ther; 2012 Nov; 36(9):866-74. PubMed ID: 22966967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
    Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
    J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
    Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
    Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
    Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance proton pump inhibitor use and risk of colorectal cancer: a Swedish retrospective cohort study.
    Liu Q; Wang X; Engstrand L; Sadr-Azodi O; Fall K; Brusselaers N
    BMJ Open; 2024 Jul; 14(7):e079591. PubMed ID: 38960460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
    Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
    Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
    Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
    Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
    Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
    BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study.
    Chen CB; Lin M; Eurich DT; Johnson JA
    Clin Ther; 2016 Jun; 38(6):1392-1400. PubMed ID: 27061884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
    Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
    Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.